KR20250053980A - 서방형 팔리페리돈 주사용 제형과 관련된 투약 요법 - Google Patents

서방형 팔리페리돈 주사용 제형과 관련된 투약 요법 Download PDF

Info

Publication number
KR20250053980A
KR20250053980A KR1020257011387A KR20257011387A KR20250053980A KR 20250053980 A KR20250053980 A KR 20250053980A KR 1020257011387 A KR1020257011387 A KR 1020257011387A KR 20257011387 A KR20257011387 A KR 20257011387A KR 20250053980 A KR20250053980 A KR 20250053980A
Authority
KR
South Korea
Prior art keywords
dose
suspension
pp6m
paliperidone palmitate
paliperidone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020257011387A
Other languages
English (en)
Korean (ko)
Inventor
스리하리 고팔
라자 벤카타수브라마니안
휴이브래츠 티'졸린
Original Assignee
얀센 파마슈티카 엔브이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=75888043&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20250053980(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 얀센 파마슈티카 엔브이 filed Critical 얀센 파마슈티카 엔브이
Publication of KR20250053980A publication Critical patent/KR20250053980A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020257011387A 2020-11-30 2021-05-07 서방형 팔리페리돈 주사용 제형과 관련된 투약 요법 Pending KR20250053980A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063119405P 2020-11-30 2020-11-30
US63/119,405 2020-11-30
KR1020237021429A KR102794804B1 (ko) 2020-11-30 2021-05-07 서방형 팔리페리돈 주사용 제형과 관련된 투약 요법
PCT/EP2021/062147 WO2022111859A1 (en) 2020-11-30 2021-05-07 Dosing regimens associated with extended release paliperidone injectable formulations

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020237021429A Division KR102794804B1 (ko) 2020-11-30 2021-05-07 서방형 팔리페리돈 주사용 제형과 관련된 투약 요법

Publications (1)

Publication Number Publication Date
KR20250053980A true KR20250053980A (ko) 2025-04-22

Family

ID=75888043

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020257011387A Pending KR20250053980A (ko) 2020-11-30 2021-05-07 서방형 팔리페리돈 주사용 제형과 관련된 투약 요법
KR1020237021429A Active KR102794804B1 (ko) 2020-11-30 2021-05-07 서방형 팔리페리돈 주사용 제형과 관련된 투약 요법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020237021429A Active KR102794804B1 (ko) 2020-11-30 2021-05-07 서방형 팔리페리돈 주사용 제형과 관련된 투약 요법

Country Status (22)

Country Link
US (3) US11304951B1 (cg-RX-API-DMAC7.html)
EP (2) EP4025188B1 (cg-RX-API-DMAC7.html)
JP (2) JP7792959B2 (cg-RX-API-DMAC7.html)
KR (2) KR20250053980A (cg-RX-API-DMAC7.html)
CN (1) CN116583270A (cg-RX-API-DMAC7.html)
AU (3) AU2021386450B2 (cg-RX-API-DMAC7.html)
CA (1) CA3203566A1 (cg-RX-API-DMAC7.html)
DK (1) DK4025188T3 (cg-RX-API-DMAC7.html)
ES (1) ES2973583T3 (cg-RX-API-DMAC7.html)
FI (1) FI4025188T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20240074T1 (cg-RX-API-DMAC7.html)
HU (1) HUE065573T2 (cg-RX-API-DMAC7.html)
IL (1) IL303253A (cg-RX-API-DMAC7.html)
LT (1) LT4025188T (cg-RX-API-DMAC7.html)
MX (2) MX2023006366A (cg-RX-API-DMAC7.html)
PL (1) PL4025188T3 (cg-RX-API-DMAC7.html)
PT (1) PT4025188T (cg-RX-API-DMAC7.html)
RS (1) RS65178B1 (cg-RX-API-DMAC7.html)
SI (1) SI4025188T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400077T1 (cg-RX-API-DMAC7.html)
TW (2) TWI877363B (cg-RX-API-DMAC7.html)
WO (1) WO2022111859A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4025188B1 (en) * 2020-11-30 2024-01-10 Janssen Pharmaceutica NV Dosing regimens associated with extended release paliperidone injectable formulations
PL4005555T3 (pl) 2020-11-30 2024-09-02 Janssen Pharmaceutica Nv Sposoby zapewniania ponownego zawieszenia preparatów palmitynianu paliperydonu
SI4025187T1 (sl) 2020-11-30 2024-03-29 Janssen Pharmaceutica Nv Režimi odmerjanja, povezani s formulacijami paliperidona za injiciranje s podaljšanim sproščanjem
CN116528836A (zh) 2020-11-30 2023-08-01 詹森药业有限公司 与延长释放帕潘立酮可注射制剂相关的给药方案
MX2024002215A (es) 2021-08-20 2024-05-10 Janssen Pharmaceutica Nv Regímenes de dosificación asociados con formulaciones inyectables de paliperidona de liberación prolongada.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5158952A (en) 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
US5254556A (en) 1988-11-07 1993-10-19 Janssen Pharmaceutica N.V. 3-piperidinyl-1,2-benzisoxazoles
TW487572B (en) 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
CN101163702B (zh) 2005-04-25 2011-09-07 詹森药业有限公司 制备无菌的3-[2-[4-(6-氟-1,2-苯并异唑-3-基)-1-哌啶基]乙基]-6,7,8,9-四氢-9-羟基-2-甲基-4H-吡啶并[1,2-a]嘧啶-4-酮棕榈酸酯的方法
CA2655335C (en) * 2007-12-19 2016-09-06 Janssen Pharmaceutica N.V. Prolonged-release injectable suspensions of paliperidone palmitate, and dosage forms and delivery systems incorporating same
US8758780B2 (en) 2009-10-06 2014-06-24 Ascendis Pharma As Subcutaneous paliperidone composition
AU2010313290A1 (en) * 2009-10-30 2012-05-17 Janssen Pharmaceutica Nv Dosing regimen associated with long-acting injectable paliperidone esters
SI2529757T1 (sl) 2011-05-31 2014-05-30 Laboratorios Farmaceuticos Rovi, S.A. Formulacija paliperidon implantata
WO2016157061A1 (en) * 2015-03-31 2016-10-06 Wockhardt Limited Aseptic wet milling process for paliperidone palmitate
DK3744326T3 (da) * 2015-04-07 2024-02-05 Janssen Pharmaceutica Nv Doseringsregime for glemte doser til langtidsvirkende injicerbare paliperidonestere
CN114783258A (zh) 2015-06-19 2022-07-22 詹森药业有限公司 用于药物施用和混合的系统及用于所述系统的适当技术的训练
US20190183896A1 (en) * 2017-12-14 2019-06-20 SpecGx LLC One step milling process for preparing micronized paliperidone esters
EP4025188B1 (en) * 2020-11-30 2024-01-10 Janssen Pharmaceutica NV Dosing regimens associated with extended release paliperidone injectable formulations

Also Published As

Publication number Publication date
KR20230116013A (ko) 2023-08-03
PT4025188T (pt) 2024-02-29
AU2021386450A9 (en) 2025-03-13
EP4025188B1 (en) 2024-01-10
IL303253A (en) 2023-07-01
DK4025188T3 (da) 2024-03-04
JP7792959B2 (ja) 2025-12-26
ES2973583T3 (es) 2024-06-20
CA3203566A1 (en) 2022-06-02
JP2026027255A (ja) 2026-02-18
AU2026203613A1 (en) 2026-05-28
HRP20240074T1 (hr) 2024-03-29
AU2024204213A1 (en) 2024-07-11
US20260060986A1 (en) 2026-03-05
US20220249495A1 (en) 2022-08-11
KR102794804B1 (ko) 2025-04-10
CN116583270A (zh) 2023-08-11
HUE065573T2 (hu) 2024-06-28
AU2021386450A1 (en) 2023-07-13
PL4025188T3 (pl) 2024-06-17
EP4356966A3 (en) 2024-07-17
TW202222319A (zh) 2022-06-16
RS65178B1 (sr) 2024-03-29
EP4356966A2 (en) 2024-04-24
TW202539685A (zh) 2025-10-16
SI4025188T1 (sl) 2024-03-29
TWI926646B (zh) 2026-05-21
US11304951B1 (en) 2022-04-19
AU2024204213B2 (en) 2026-02-26
AU2021386450B2 (en) 2024-03-21
SMT202400077T1 (it) 2024-03-13
TWI877363B (zh) 2025-03-21
JP2023552329A (ja) 2023-12-15
MX2023006366A (es) 2023-08-07
LT4025188T (lt) 2024-03-12
WO2022111859A1 (en) 2022-06-02
MX2024009188A (es) 2024-08-06
EP4025188A1 (en) 2022-07-13
FI4025188T3 (fi) 2024-02-21

Similar Documents

Publication Publication Date Title
KR102794804B1 (ko) 서방형 팔리페리돈 주사용 제형과 관련된 투약 요법
TWI838623B (zh) 與延釋帕利哌酮可注射配製物相關之投藥方案(二)
US12053474B2 (en) Dosing regimens associated with extended release paliperidone injectable formulations
KR20240049580A (ko) 서방형 팔리페리돈 주사용 제형과 관련된 투약 요법
EA049114B1 (ru) Схемы применения инъекционных составов с пролонгированным высвобождением палиперидона

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000